share_log

Sisram Medical's (HKG:1696) three-year earnings growth trails the 54% YoY shareholder returns

Simply Wall St ·  Jun 19, 2022 20:37

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For instance the Sisram Medical Ltd (HKG:1696) share price is 248% higher than it was three years ago. That sort of return is as solid as granite. It's also up 75% in about a month.

On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.

View our latest analysis for Sisram Medical

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

Sisram Medical was able to grow its EPS at 11% per year over three years, sending the share price higher. In comparison, the 52% per year gain in the share price outpaces the EPS growth. This indicates that the market is feeling more optimistic on the stock, after the last few years of progress. It is quite common to see investors become enamoured with a business, after a few years of solid progress.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

SEHK:1696 Earnings Per Share Growth June 20th 2022

We know that Sisram Medical has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Sisram Medical will grow revenue in the future.

What About Dividends?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Sisram Medical the TSR over the last 3 years was 265%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!

A Different Perspective

We can sympathize with Sisram Medical about their 8.2% loss for the year ( including dividends), but the silver lining is that the broader market return was worse, at around -21%. Longer term investors wouldn't be so upset, since they would have made 54%, each year, over three years. It's possible that the recent share price decline has more to do with the negative broader market returns than any company specific development. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Sisram Medical you should know about.

But note: Sisram Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment